Alembic Peer Comparison

Alembic Ltd. shows strong revenue growth and profitability metrics compared to its peers in the Pharmaceuticals & Drugs industry. The company is positioned well with low debt levels, making it an attractive investment choice. However, some peers display higher profitability and lower valuations, suggesting areas of potential opportunity for investors.

• • Alembic Ltd. leads in revenue growth YoY (23.77%) and has low debt-equity ratio (0.0042).
• • Divi's Laboratories has the highest EPS (82.53) but also has a high PE ratio (73.20), indicating potential overvaluation.
• • Dr. Reddy's Laboratories ranks high in profitability metrics with ROE (21.76%) and ROCE (26.86%).
• • Cipla Ltd. offers a strong PEG ratio (0.35), indicating good growth potential relative to its valuation.
• • Mankind Pharma shows significant revenue growth over 3 years (155.25%), suggesting robust expansion.

• • Dr. Reddy's Laboratories Ltd.: High profitability with ROE of 21.76% and low PE ratio of 15.50.
• • Cipla Ltd.: Strong growth and profitability with ROE of 16.63% and attractive PEG ratio of 0.35.
• • Mankind Pharma Ltd.: Outstanding revenue growth (155.25% over 3 years) with manageable debt levels.